NOVAVAX INC

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

NVAX$10.20-6.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of December 31, 202 and

(in thousands, except share and per share information)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$568,505	$1,336,883
Restricted cash	10,424	10,303
Accounts receivable	297,240	82,375
Inventory	41,696	36,683
Prepaid expenses and other current assets	226,023	237,147
Total current assets	1,143,888	1,703,391
Property and equipment, net	305,771	294,247
Right of use asset, net	185,218	106,241
Goodwill	127,454	126,331
Other non-current assets	35,159	28,469
Total assets	$1,797,490	$2,258,679
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$132,610	$216,517
Accrued expenses	394,668	591,158
Deferred revenue	241,310	370,137
Current portion of finance lease liabilities	5,142	27,196
Convertible notes payable	—	324,881
Other current liabilities	861,408	930,055
Total current liabilities	1,635,138	2,459,944
Deferred revenue	622,210	179,414
Convertible notes payable	168,016	166,466
Non-current finance lease liabilities	55,923	31,238
Other non-current liabilities	33,130	55,695
Total liabilities	2,514,417	2,892,757
Commitments and contingencies (Note 16)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022	—	—
Stockholders’ deficit:
Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2023 and 2022; and 140,506,093 shares issued and 139,505,770 shares outstanding at December 31, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 2022	1,405	868
Additional paid-in capital	4,192,164	3,737,979
Accumulated deficit	(4,820,951)	(4,275,889)
Treasury stock, 1,000,323 shares, cost basis at December 31, 2023 and 766,631 shares, cost basis at December 31, 2022	(92,267)	(90,659)
Accumulated other comprehensive income (loss)	2,722	(6,377)
Total stockholders’ deficit	(716,927)	(634,078)
Total liabilities and stockholders’ deficit	$1,797,490	$2,258,679

F- 7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.